SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19-Reference-Cited by-同舟云学术

SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19

Published:2022-06-17 Issue:6 Volume:2022 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Hirsch Caroline¹,Park Yun Soo¹,Piechotta Vanessa¹,Chai Khai Li²,Estcourt Lise J³,Monsef Ina¹,Salomon Susanne⁴,Wood Erica M²,So-Osman Cynthia⁵,McQuilten Zoe²,Spinner Christoph D⁶,Malin Jakob J⁷⁸,Stegemann Miriam⁹,Skoetz Nicole¹,Kreuzberger Nina¹

Affiliation:

1. Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany

2. Transfusion Research Unit, School of Public Health and Preventive Medicine; Monash University; Melbourne Australia

3. Haematology/Transfusion Medicine; NHS Blood and Transplant; Oxford UK

4. Laboratory of Experimental Immunology, Institute of Virology; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany

5. Erasmus Medical Centre; Rotterdam Netherlands

6. School of Medicine; Technical University of Munich; Munich Germany

7. Department I for Internal Medicine, Division of Infectious Diseases; University of Cologne, Faculty of Medicine and University Hospital Cologne; Cologne Germany

8. Center for Molecular Medicine Cologne (CMMC); Faculty of Medicine, University of Cologne; Cologne Germany

9. Department of Infectious Diseases and Respiratory Medicine; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Berlin Germany

Publisher

Wiley

Subject

Pharmacology (medical)

Reference190 articles.

1. Cohen MS Nirula A Mulligan M Novak R Marovich M Stemer A Bamlanivimab prevents COVID-19 morbidity and mortality in nursing-home setting, 2021 www.croiconference.org/abstract/bamlanivimab-prevents-covid-19-morbidity-and-mortality-in-nursing-home-setting/

2. Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial;Cohen;JAMA,2021

3. Innovative clinical trial design and delivery: a phase 3 COVID-19 post-exposure prophylaxis study in skilled nursing and assisted living facilities (BLAZE-2);Knorr;Trials,2021

4. Isa F Forleo-Neto E Meyer J Zheng W Rasmussen S Armas D Repeat subcutaneous administration of REGEN-COV in adults is well-tolerated and prevents the occurrence of COVID-19 medRxiv [Preprint] 2021 10.1101/2021.11.10.21265889

5. P-071: pharmacokinetics and immunogenicity assessment of a single subcutaneous dose of casirivimab and imdevimab in household contacts of SARS-CoV-2 infected persons;Hassan;American Society for Clinical Pharmacology and Therapeutics

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of convalescent plasma and hyperimmune immunoglobulins in the COVID-19 pandemic, including implications for future preparedness;Frontiers in Immunology;2024-09-09

2. A unifying model to explain frequent SARS-CoV-2 rebound after nirmatrelvir treatment and limited prophylactic efficacy;Nature Communications;2024-06-28

3. Functional diversification of innate and inflammatory immune responses mediated by antibody fragment crystallizable activities against SARS-CoV-2;iScience;2024-05

4. COVID-19 antibody titers after tixagevimab–cilgavimab injection in patients with hematologic diseases; a single-center, prospective study;Leukemia & Lymphoma;2024-04-16

5. Adverse events related to drug–drug interactions in COVID-19 patients. A persistent concern in the post-pandemic era: a systematic review;Expert Opinion on Drug Metabolism & Toxicology;2024-04-02